The National Psoriasis Foundation issued a new position statement that clarifies the definition of psoriasis disease severity ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. It depends on how much psoriasis someone ...

German registry data suggest apremilast monotherapy improves psoriasis severity and quality of life over 12 months, with ...

Metabolic bariatric surgery is associated with improved outcomes in patients with psoriasis, according to a recent study.

Patients with psoriasis often have comorbidities that are linked to the systemic inflammation of psoriasis and its treatment, according to study findings published in The Journal of Dermatology. The ...

Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis. Half of ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In patients with plaque psoriasis, studies have shown that ...

Older adults with severe or refractory psoriatic disease face a unique challenge: Balancing the need for effective systemic treatment with the increased risk for serious infections. A cohort study ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

Real-world registry data from Germany show apremilast improves psoriasis severity and quality of life, with a safety profile consistent with clinical trials.

Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, systemic therapies, and more to manage symptoms.